Overall, these results suggested that JX could suppress tumor angiogenesis and promote the infiltration of CD11c+ DCs and CD8+ T cells into tumor nodules, eliciting an effective antitumor immune response in TME. The gene discussed is ITGAX; the disease is neoplasm.